Assessing clinical utility of preconception expanded carrier screening regarding residual risk for neurodevelopmental disorders

Boonsawat P, Horn AHC, Steindl K, Baumer A, Joset P, Kraemer D, Bahr A, Ivanovski I, Cabello EM, Papik M, Zweier M, Oneda B, Sirleto P, Burkhardt T, Sticht H, Rauch A (2022)


Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 7

Article Number: 45

Journal Issue: 1

DOI: 10.1038/s41525-022-00316-x

Abstract

The magnitude of clinical utility of preconception expanded carrier screening (ECS) concerning its potential to reduce the risk of affected offspring is unknown. Since neurodevelopmental disorders (NDDs) in their offspring is a major concern of parents-to-be, we addressed the question of residual risk by assessing the risk-reduction potential for NDDs in a retrospective study investigating ECS with different criteria for gene selection and definition of pathogenicity. We used exome sequencing data from 700 parents of children with NDDs and blindly screened for carrier-alleles in up to 3046 recessive/X-linked genes. Depending on variant pathogenicity thresholds and gene content, NDD-risk-reduction potential was up to 43.5% in consanguineous, and 5.1% in nonconsanguineous couples. The risk-reduction-potential was compromised by underestimation of pathogenicity of missense variants (false-negative-rate 4.6%), inherited copy-number variants and compound heterozygosity of one inherited and one de novo variant (0.9% each). Adherence to the ACMG recommendations of restricting ECS to high-frequency genes in nonconsanguineous couples would more than halve the detectable inherited NDD-risk. Thus, for optimized clinical utility of ECS, screening in recessive/X-linked genes regardless of their frequency (ACMG Tier-4) and sensible pathogenicity thresholds should be considered for all couples seeking ECS.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Boonsawat, P., Horn, A.H.C., Steindl, K., Baumer, A., Joset, P., Kraemer, D.,... Rauch, A. (2022). Assessing clinical utility of preconception expanded carrier screening regarding residual risk for neurodevelopmental disorders. npj Genomic Medicine, 7(1). https://dx.doi.org/10.1038/s41525-022-00316-x

MLA:

Boonsawat, Paranchai, et al. "Assessing clinical utility of preconception expanded carrier screening regarding residual risk for neurodevelopmental disorders." npj Genomic Medicine 7.1 (2022).

BibTeX: Download